The growth of Cogent Biosciences Inc (COGT) Stock is expected to continue

Robert W. Baird lowered the price target for the Cogent Biosciences Inc (NASDAQ:COGT) stock from “an Outperform” to “a Neutral”. The rating was released on February 26, 2024, according to finviz. The research report from Wedbush has downgraded the stock from Outperform to Neutral, with a price target set at $5. The stock was initiated by JP Morgan, who disclosed in a research note on December 08, 2023, to Overweight and set the price objective to $18. In their research brief published April 28, 2023, Robert W. Baird analysts initiated the Cogent Biosciences Inc stock to Outperform with a price target of $20.

The latest trade, Performances and Moving Averages give us the following Picture

The firm’s stock price fluctuated 7.98% within the last five trades and -1.43% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -29.59% in the last 6 months and 14.05% was added to its value over the previous 3 months. COGT stock is trading at a margin of 3.97%, 8.55% and -21.78% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


As of the close of trading, COGT deals in the Healthcare domain. The stock is trading -48.89 percent below its 52-week high and 88.01 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -34.6. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.

What Does Cogent Biosciences Inc’s Profitability and Valuation Ratios Tell Us About the Stock?

With regard to the profitability of the company, the operating margin is currently at 0.00 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.

The stock’s market cap achieved a total value of $716.98 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The firm managed a Price-to-Book ratio of 3.00, which equates the market value of a stock with its book value.

Is Insider Trading a Real Thing?

Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 16.06 percent of Cogent Biosciences Inc shares are owned by insiders, and 75.78 percent are held by financial institutions. Fairmount Funds Management LLC, the 10% Owner at Cogent Biosciences Inc (COGT) has bought 800,000 shares of firm on Jun 09 ’23 at a price of $12.00 against the total amount of $9.6 million.

Most Popular

Related Posts